Biogen/Eisai's Leqembi Brings Hope To Early Alzheimer's Patients Amid Logistical Challenges
Biogen/Eisai's Leqembi Brings Hope To Early Alzheimer's Patients Amid Logistical Challenges
Biogen Inc. (NASDAQ:BIIB) and Eisai Ltd's (OTC:ESALY) Alzheimer's drug Leqembi (lecanemab) is reportedly offering hope for patients in the early stages of the disease despite it not being a cure.
据报道,百健公司(纳斯达克股票代码:BIIB)和卫材有限公司(场外交易代码:ESALY)的阿尔茨海默氏症药物Leqembi(lecanemab)尽管无法治愈,但仍为处于该疾病早期阶段的患者带来了希望。
For many, like Mississippi English professor Missie Meeks, the treatment is helping to slow the progression of Alzheimer's, allowing her to maintain independence in daily life.
对于许多人来说,例如密西西比英语教授米西·米克斯,这种治疗有助于减缓阿尔茨海默氏症的进展,使她能够在日常生活中保持独立性。
Also Read: Biogen's Higher Dose Spinraza Shows To Slow Neurodegeneration Faster In Infants With Rare Neuromuscular Disorder.
另请阅读:Biogen的更高剂量Spinraza显示可以更快地减缓患有罕见神经肌肉疾病的婴儿的神经变性。
Meeks, who was diagnosed with Alzheimer's ahead of her 50th birthday, has been receiving biweekly infusions of Leqembi since September 2023, giving her more time to function independently, even if the treatment hasn't eliminated her cognitive struggles.
米克斯在50岁生日之前被诊断出患有阿尔茨海默氏症,自2023年9月以来,她每两周接受一次Leqembi注射,这使她有更多时间独立运作,即使治疗没有消除她的认知障碍。
Leqembi, a monoclonal antibody, moderately slows memory and cognitive decline in patients with mild cognitive impairment.
Leqembi是一种单克隆抗体,可适度减缓轻度认知障碍患者的记忆力和认知能力下降。
While the drug represents a significant advancement, its rollout has faced several logistical challenges, including diagnostic bottlenecks, insurance issues, and a limited number of neurologists qualified to prescribe it.
尽管该药物取得了重大进展,但其推出面临着多项后勤挑战,包括诊断瓶颈、保险问题以及有资格开处方的神经科医生数量有限。
Patients need to undergo extensive testing, including PET and MRI scans, to confirm their eligibility, with some clinics even requiring genetic testing due to the drug's potential side effects, like brain swelling and bleeding.
患者需要接受广泛的检测,包括pET和MRI扫描,以确认其资格,由于该药物的潜在副作用,例如脑肿胀和出血,一些诊所甚至需要进行基因检测。
Concerns remain over the drug's side effects and long-term benefits.
人们仍然对该药物的副作用和长期益处感到担忧。
Some neurologists are cautious about prescribing it, while others acknowledge the difficulties in managing its rollout, citing the steep learning curve.
一些神经科医生对开处方持谨慎态度,而另一些神经科医生则承认在管理其推出方面存在困难,理由是学习曲线很陡峭。
Despite these concerns, CNBC writes that the patients believe the treatment's benefits outweigh the risks.
尽管有这些担忧,CNBC写道,患者认为治疗的益处大于风险。
Sales of Leqembi have grown since its approval in July 2023, with Biogen reporting nearly $60 million in revenue from the drug in the first half of 2024.
自2023年7月获得批准以来,Leqembi的销售额有所增长,Biogen报告称,该药物在2024年上半年收入接近6000万美元。
The company is working on simplifying treatment administration, including potential subcutaneous injections and extended infusion intervals, to make the drug more accessible for patients.
该公司正在努力简化治疗管理,包括可能的皮下注射和延长输液间隔,以使患者更容易获得该药物。
In August, Biogen's lecanemab became the first treatment for early AD (MCI and mild dementia due to AD) that targets an underlying cause of the disease to be authorized in a European country.
8月,Biogen的lecanemab成为欧洲国家批准的第一种针对该疾病根本原因的早期AD(MCI和由AD引起的轻度痴呆)的治疗方法。
Despite the approval, the National Institute for Health and Care Excellence (NICE), in its guidance draft, said, "benefits of the new Alzheimer's drug lecanemab are too small to justify the costs."
尽管获得批准,但美国国家健康与护理卓越研究所(NICE)在其指导草案中表示:“阿尔茨海默氏症新药lecanemab的益处太小,不足以证明成本是合理的。”
Price Action: At last check on Monday, BIIB stock was down 0.43% to $199.71.
价格走势:在周一的最后一次检查中,BiIB股价下跌0.43%,至199.71美元。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免责声明:此内容部分是在人工智能工具的帮助下制作的,并由Benzinga的编辑审阅和发布。
- DoubleVerify's Politics-Focused Inflammatory News Category Rolls Out On Meta: Details.
- DoubleVerify以政治为重点的煽动性新闻类别在Meta上线:详情。